Burning Rock Biotech Limited (NASDAQ:BNR) Short Interest Down 6.6% in December

Burning Rock Biotech Limited (NASDAQ:BNR) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 60,500 shares, a decrease of 6.6% from the December 15th total of 64,800 shares. Currently, 0.7% of the company’s shares are short sold. Based on an average trading volume of 26,300 shares, the days-to-cover ratio is currently 2.3 days.

Burning Rock Biotech Price Performance

NASDAQ BNR traded up $0.25 during trading hours on Friday, reaching $6.75. 308 shares of the company’s stock were exchanged, compared to its average volume of 7,089. The company’s 50-day moving average is $6.15 and its two-hundred day moving average is $5.29. Burning Rock Biotech has a one year low of $2.62 and a one year high of $9.80.

Institutional Trading of Burning Rock Biotech

A hedge fund recently bought a new stake in Burning Rock Biotech stock. SkyView Investment Advisors LLC bought a new position in shares of Burning Rock Biotech Limited (NASDAQ:BNR) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $64,000. SkyView Investment Advisors LLC owned approximately 0.10% of Burning Rock Biotech as of its most recent filing with the Securities and Exchange Commission. 30.03% of the stock is owned by institutional investors.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.